Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson reports phase IIb TMC278 results

Johnson and Johnson reports phase IIb TMC278 results

6th August 2008

Tibotec Pharmaceuticals, a Johnson & Johnson company, has announced the publication of 96-week data from a phase IIb study examining the safety and efficacy of once-daily therapy with TMC278 in treatment-naive HIV-1 patients.

The data was presented at the International AIDS Conference held in Mexico City.

Study results showed 76 per cent of patients administered with a 25mg dose of TMC278 achieved an undetectable viral load at week 96, compared to 72 per cent of those patients treated with efavirenz.

Additionally, 72 per cent of patients receiving a 75mg dose of the drug showed an undetectable viral load, as did 71 per cent of those treated with a 150mg dose.

TMC278 is a once-daily investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) given in conjunction with HIV combination therapy.

Peter Shalit, of the Swedish Medical Centre in Seattle, said: “NNRTIs have been an integral part of combination antiretroviral therapy for over a decade.”

He added these study results show the potential of TMC278 as a treatment option in patients who have not yet taken medication for HIV.

In July 2007, Tibotec Pharmaceuticals announced the publication of positive phase III clinical trial results of Prezista (darunavir) with ritonavir taken with an optimised antiretroviral agent background regimen in HIV-1 patients who are treatment-experienced.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.